View Future GrowthCanBas 過去の業績過去 基準チェック /06CanBasの収益は年間平均-15.8%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間13.3% 93.7%割合で 減少しています。主要情報-15.80%収益成長率3.82%EPS成長率Biotechs 業界の成長31.91%収益成長率-93.68%株主資本利益率-57.84%ネット・マージンn/a次回の業績アップデート12 Aug 2026最近の業績更新お知らせ • Jun 03CanBas Co., Ltd. to Report Fiscal Year 2026 Results on Aug 12, 2026CanBas Co., Ltd. announced that they will report fiscal year 2026 results on Aug 12, 2026お知らせ • Sep 01+ 2 more updatesCanBas Co., Ltd. to Report Q2, 2026 Results on Feb 13, 2026CanBas Co., Ltd. announced that they will report Q2, 2026 results on Feb 13, 2026お知らせ • Jun 03CanBas Co., Ltd. to Report Fiscal Year 2025 Results on Aug 08, 2025CanBas Co., Ltd. announced that they will report fiscal year 2025 results on Aug 08, 2025お知らせ • Aug 28+ 2 more updatesCanBas Co., Ltd. to Report Q2, 2025 Results on Feb 13, 2025CanBas Co., Ltd. announced that they will report Q2, 2025 results on Feb 13, 2025お知らせ • Jun 05CanBas Co., Ltd. to Report Fiscal Year 2024 Results on Aug 09, 2024CanBas Co., Ltd. announced that they will report fiscal year 2024 results on Aug 09, 2024お知らせ • Sep 03+ 2 more updatesCanBas Co., Ltd. to Report Q3, 2024 Results on May 10, 2024CanBas Co., Ltd. announced that they will report Q3, 2024 results on May 10, 2024すべての更新を表示Recent updatesお知らせ • Jun 03CanBas Co., Ltd. to Report Fiscal Year 2026 Results on Aug 12, 2026CanBas Co., Ltd. announced that they will report fiscal year 2026 results on Aug 12, 2026分析記事 • May 20Is CanBas (TSE:4575) In A Good Position To Deliver On Growth Plans?We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...New Risk • Mar 03New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: JP¥14.7b (US$93.3m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.6% average weekly change). Earnings have declined by 17% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (JP¥14.7b market cap, or US$93.3m).分析記事 • Feb 03We Think CanBas (TSE:4575) Can Easily Afford To Drive Business GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, although...New Risk • Nov 04New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: JP¥15.3b (US$99.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 20% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (JP¥15.3b market cap, or US$99.9m).お知らせ • Sep 01+ 2 more updatesCanBas Co., Ltd. to Report Q2, 2026 Results on Feb 13, 2026CanBas Co., Ltd. announced that they will report Q2, 2026 results on Feb 13, 2026お知らせ • Aug 08CanBas Co., Ltd., Annual General Meeting, Sep 29, 2025CanBas Co., Ltd., Annual General Meeting, Sep 29, 2025.お知らせ • Jun 03CanBas Co., Ltd. to Report Fiscal Year 2025 Results on Aug 08, 2025CanBas Co., Ltd. announced that they will report fiscal year 2025 results on Aug 08, 2025分析記事 • Apr 08CanBas (TSE:4575) Is In A Good Position To Deliver On Growth PlansJust because a business does not make any money, does not mean that the stock will go down. For example, although...New Risk • Apr 07New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: JP¥14.2b (US$97.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.8% average weekly change). Earnings have declined by 20% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (JP¥14.2b market cap, or US$97.1m).分析記事 • Dec 16Here's Why We're Not Too Worried About CanBas' (TSE:4575) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...お知らせ • Aug 28+ 2 more updatesCanBas Co., Ltd. to Report Q2, 2025 Results on Feb 13, 2025CanBas Co., Ltd. announced that they will report Q2, 2025 results on Feb 13, 2025お知らせ • Aug 09CanBas Co., Ltd., Annual General Meeting, Sep 27, 2024CanBas Co., Ltd., Annual General Meeting, Sep 27, 2024.分析記事 • Jun 26CanBas (TSE:4575) Is In A Good Position To Deliver On Growth PlansThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...お知らせ • Jun 05CanBas Co., Ltd. to Report Fiscal Year 2024 Results on Aug 09, 2024CanBas Co., Ltd. announced that they will report fiscal year 2024 results on Aug 09, 2024分析記事 • Feb 26We're Hopeful That CanBas (TSE:4575) Will Use Its Cash WiselyThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...New Risk • Feb 01New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: JP¥14.7b (US$99.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 20% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (5.8% average weekly change). Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (JP¥14.7b market cap, or US$99.8m).New Risk • Oct 23New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 7.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥1.4b free cash flow). Share price has been highly volatile over the past 3 months (7.4% average weekly change). Earnings have declined by 18% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Shareholders have been diluted in the past year (24% increase in shares outstanding).お知らせ • Sep 03+ 2 more updatesCanBas Co., Ltd. to Report Q3, 2024 Results on May 10, 2024CanBas Co., Ltd. announced that they will report Q3, 2024 results on May 10, 2024New Risk • Aug 24New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 7.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥1.4b free cash flow). Share price has been highly volatile over the past 3 months (7.5% average weekly change). Earnings have declined by 18% per year over the past 5 years. Shareholders have been substantially diluted in the past year (50% increase in shares outstanding). Revenue is less than US$1m.New Risk • Aug 17New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -JP¥1.4b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥1.4b free cash flow). Earnings have declined by 18% per year over the past 5 years. Shareholders have been substantially diluted in the past year (50% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Share price has been volatile over the past 3 months (7.3% average weekly change).お知らせ • Aug 12CanBas Co., Ltd., Annual General Meeting, Sep 26, 2023CanBas Co., Ltd., Annual General Meeting, Sep 26, 2023.New Risk • Aug 07New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 50% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 15% per year over the past 5 years. Shareholders have been substantially diluted in the past year (50% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Share price has been volatile over the past 3 months (6.8% average weekly change).お知らせ • Jun 03+ 1 more updateCanBas Co., Ltd. to Report Fiscal Year 2023 Results on Aug 10, 2023CanBas Co., Ltd. announced that they will report fiscal year 2023 results on Aug 10, 2023お知らせ • May 20CanBas Co., Ltd. announced that it expects to receive ¥729 million in fundingCanBas Co., Ltd. announced a private placement of 500,000 common shares at an issue price of ¥1,458 per share for the gross proceeds of ¥729,000,000 on May 18, 2023. The transaction will include participation from new investors Long Corridor Alpha Opportunities Master Fund and MAP246 Segregated Portfolio. The company will issue shares through third-party allotment. The transaction has been approved by the board of directors of the company. The transaction is expected to close on June 2, 2023.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 3 highly experienced directors. 2 independent directors (5 non-independent directors). Independent External Director Toshio Furuta was the last independent director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Sep 01+ 2 more updatesCanBas Co., Ltd. to Report Q3, 2023 Results on May 12, 2023CanBas Co., Ltd. announced that they will report Q3, 2023 results on May 12, 2023Reported Earnings • Aug 15Full year 2022 earnings released: JP¥88.26 loss per share (vs JP¥70.01 loss in FY 2021)Full year 2022 results: JP¥88.26 loss per share (down from JP¥70.01 loss in FY 2021). Net loss: JP¥855.0m (loss widened 61% from FY 2021). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.お知らせ • Aug 14CanBas Co., Ltd., Annual General Meeting, Sep 27, 2022CanBas Co., Ltd., Annual General Meeting, Sep 27, 2022.お知らせ • Jun 03CanBas Co., Ltd. to Report Fiscal Year 2022 Results on Aug 12, 2022CanBas Co., Ltd. announced that they will report fiscal year 2022 results on Aug 12, 2022Reported Earnings • May 19Third quarter 2022 earnings released: JP¥22.78 loss per share (vs JP¥9.24 loss in 3Q 2021)Third quarter 2022 results: JP¥22.78 loss per share (down from JP¥9.24 loss in 3Q 2021). Net loss: JP¥224.0m (loss widened 215% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 3 highly experienced directors. 2 independent directors (5 non-independent directors). Independent External Director Toshio Furuta was the last independent director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Feb 12First half 2022 earnings: Revenues and EPS in line with analyst expectationsFirst half 2022 results: JP¥39.87 loss per share (up from JP¥43.73 loss in 1H 2021). Net loss: JP¥359.0m (loss widened 16% from 1H 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.Reported Earnings • Nov 12First quarter 2022 earnings released: JP¥22.38 loss per share (vs JP¥29.76 loss in 1Q 2021)First quarter 2022 results: Net loss: JP¥198.0m (loss narrowed 5.7% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings.お知らせ • Sep 03CanBas Co., Ltd. announced that it expects to receive ¥16.38843 million in fundingCanBas Co., Ltd. announced a private placement of 55,554 units at a price of ¥295 for gross proceeds of ¥16,388,430 on September 2, 2021. The company has issued through 17th Stock Acquisition Rights. As part of the transaction, no monetary payment is required in exchange for the bonds with Stock Acquisition Rights.Reported Earnings • May 17Third quarter 2021 earnings released: JP¥9.24 loss per share (vs JP¥19.46 loss in 3Q 2020)The company reported a decent third quarter result with reduced losses and improved control over expenses, although revenues were flat. Third quarter 2021 results: Revenue: JP¥27.0m (flat on 3Q 2020). Net loss: JP¥71.0m (loss narrowed 47% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.Reported Earnings • Feb 14Second quarter 2021 earnings released: JP¥14.04 loss per share (vs JP¥18.59 loss in 2Q 2020)The company reported a decent second quarter result with reduced losses and improved control over expenses, although revenues were flat. Second quarter 2021 results: Revenue: JP¥28.0m (flat on 2Q 2020). Net loss: JP¥100.0m (loss narrowed 21% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Jan 05New 90-day low: JP¥426The company is down 40% from its price of JP¥710 on 07 October 2020. The Japanese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 11% over the same period.Is New 90 Day High Low • Dec 16New 90-day low: JP¥457The company is down 35% from its price of JP¥703 on 17 September 2020. The Japanese market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period.お知らせ • Nov 06CanBas Co., Ltd. announced that it expects to receive ¥9.678321 million in funding from Advantage Partners, Inc. and other investorsCanBas Co., Ltd. (TSE:4575) announced that it will issue 17,629 16th Stock Acquisition Rights at a price of ¥549 per stock acquisition right for the gross proceeds of ¥9,678,321 on November 5, 2020. The stock acquisition rights are converted into 1,762,900 common shares and have initial exercise of ¥610 per share and minimum exercise price of ¥305 per share. The expected fund raise through exercise of stock acquisition right are ¥1,085,047,321. The transaction include participation from existing investor Inflexion II Fund L.P., funds managed by Advantage Partners, Inc. for 4,524 stock acquisition rights, Investment Limited Partnership InfleXion II for 11,612 stock acquisition rights and Flagship Asset Management Investment Association No. 90 for 1,493 stock acquisition rights.お知らせ • Sep 12CanBas Co., Ltd. to Report Q1, 2021 Results on Nov 13, 2020CanBas Co., Ltd. announced that they will report Q1, 2021 results on Nov 13, 2020収支内訳CanBas の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史TSE:4575 収益、費用、利益 ( )JPY Millions日付収益収益G+A経費研究開発費31 Mar 260-1,199207031 Dec 250-1,245204030 Sep 250-1,209197030 Jun 250-1,157194031 Mar 250-1,487194031 Dec 240-1,296190030 Sep 240-1,311191030 Jun 240-1,209191031 Mar 240-1,086210031 Dec 230-1,074205030 Sep 230-1,116196030 Jun 230-1,244184031 Mar 230-983182031 Dec 220-1,059176030 Sep 220-979176030 Jun 220-855175031 Mar 2226-733185031 Dec 2153-580183030 Sep 2181-519182030 Jun 21108-531174031 Mar 21110-548179031 Dec 20110-610176030 Sep 20110-637178030 Jun 20110-572186031 Mar 20109-516184031 Dec 19109-571180030 Sep 19109-492166030 Jun 19115-456161031 Mar 19116-486172031 Dec 18116-435180030 Sep 18116-508189030 Jun 18110-532191031 Mar 18109-528197031 Dec 17109-463193030 Sep 17109-415193030 Jun 17109-419190031 Mar 17110-374196031 Dec 16110-485188030 Sep 16107-480173030 Jun 16105-414167031 Mar 16101-384182031 Dec 1599-255179030 Sep 1585-2561820質の高い収益: 4575は現在利益が出ていません。利益率の向上: 4575は現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: 4575は利益が出ておらず、過去 5 年間で損失は年間15.8%の割合で増加しています。成長の加速: 4575の過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: 4575は利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 4.7% ) と比較することは困難です。株主資本利益率高いROE: 4575は現在利益が出ていないため、自己資本利益率 ( -57.84% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/22 17:13終値2026/07/22 00:00収益2026/03/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋CanBas Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Kiyokazu YamazakiIchiyoshi Research Institute Inc.
お知らせ • Jun 03CanBas Co., Ltd. to Report Fiscal Year 2026 Results on Aug 12, 2026CanBas Co., Ltd. announced that they will report fiscal year 2026 results on Aug 12, 2026
お知らせ • Sep 01+ 2 more updatesCanBas Co., Ltd. to Report Q2, 2026 Results on Feb 13, 2026CanBas Co., Ltd. announced that they will report Q2, 2026 results on Feb 13, 2026
お知らせ • Jun 03CanBas Co., Ltd. to Report Fiscal Year 2025 Results on Aug 08, 2025CanBas Co., Ltd. announced that they will report fiscal year 2025 results on Aug 08, 2025
お知らせ • Aug 28+ 2 more updatesCanBas Co., Ltd. to Report Q2, 2025 Results on Feb 13, 2025CanBas Co., Ltd. announced that they will report Q2, 2025 results on Feb 13, 2025
お知らせ • Jun 05CanBas Co., Ltd. to Report Fiscal Year 2024 Results on Aug 09, 2024CanBas Co., Ltd. announced that they will report fiscal year 2024 results on Aug 09, 2024
お知らせ • Sep 03+ 2 more updatesCanBas Co., Ltd. to Report Q3, 2024 Results on May 10, 2024CanBas Co., Ltd. announced that they will report Q3, 2024 results on May 10, 2024
お知らせ • Jun 03CanBas Co., Ltd. to Report Fiscal Year 2026 Results on Aug 12, 2026CanBas Co., Ltd. announced that they will report fiscal year 2026 results on Aug 12, 2026
分析記事 • May 20Is CanBas (TSE:4575) In A Good Position To Deliver On Growth Plans?We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
New Risk • Mar 03New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: JP¥14.7b (US$93.3m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.6% average weekly change). Earnings have declined by 17% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (JP¥14.7b market cap, or US$93.3m).
分析記事 • Feb 03We Think CanBas (TSE:4575) Can Easily Afford To Drive Business GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, although...
New Risk • Nov 04New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: JP¥15.3b (US$99.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 20% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (JP¥15.3b market cap, or US$99.9m).
お知らせ • Sep 01+ 2 more updatesCanBas Co., Ltd. to Report Q2, 2026 Results on Feb 13, 2026CanBas Co., Ltd. announced that they will report Q2, 2026 results on Feb 13, 2026
お知らせ • Aug 08CanBas Co., Ltd., Annual General Meeting, Sep 29, 2025CanBas Co., Ltd., Annual General Meeting, Sep 29, 2025.
お知らせ • Jun 03CanBas Co., Ltd. to Report Fiscal Year 2025 Results on Aug 08, 2025CanBas Co., Ltd. announced that they will report fiscal year 2025 results on Aug 08, 2025
分析記事 • Apr 08CanBas (TSE:4575) Is In A Good Position To Deliver On Growth PlansJust because a business does not make any money, does not mean that the stock will go down. For example, although...
New Risk • Apr 07New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: JP¥14.2b (US$97.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.8% average weekly change). Earnings have declined by 20% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (JP¥14.2b market cap, or US$97.1m).
分析記事 • Dec 16Here's Why We're Not Too Worried About CanBas' (TSE:4575) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
お知らせ • Aug 28+ 2 more updatesCanBas Co., Ltd. to Report Q2, 2025 Results on Feb 13, 2025CanBas Co., Ltd. announced that they will report Q2, 2025 results on Feb 13, 2025
お知らせ • Aug 09CanBas Co., Ltd., Annual General Meeting, Sep 27, 2024CanBas Co., Ltd., Annual General Meeting, Sep 27, 2024.
分析記事 • Jun 26CanBas (TSE:4575) Is In A Good Position To Deliver On Growth PlansThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
お知らせ • Jun 05CanBas Co., Ltd. to Report Fiscal Year 2024 Results on Aug 09, 2024CanBas Co., Ltd. announced that they will report fiscal year 2024 results on Aug 09, 2024
分析記事 • Feb 26We're Hopeful That CanBas (TSE:4575) Will Use Its Cash WiselyThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
New Risk • Feb 01New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: JP¥14.7b (US$99.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 20% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (5.8% average weekly change). Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (JP¥14.7b market cap, or US$99.8m).
New Risk • Oct 23New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 7.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥1.4b free cash flow). Share price has been highly volatile over the past 3 months (7.4% average weekly change). Earnings have declined by 18% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Shareholders have been diluted in the past year (24% increase in shares outstanding).
お知らせ • Sep 03+ 2 more updatesCanBas Co., Ltd. to Report Q3, 2024 Results on May 10, 2024CanBas Co., Ltd. announced that they will report Q3, 2024 results on May 10, 2024
New Risk • Aug 24New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 7.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥1.4b free cash flow). Share price has been highly volatile over the past 3 months (7.5% average weekly change). Earnings have declined by 18% per year over the past 5 years. Shareholders have been substantially diluted in the past year (50% increase in shares outstanding). Revenue is less than US$1m.
New Risk • Aug 17New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -JP¥1.4b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥1.4b free cash flow). Earnings have declined by 18% per year over the past 5 years. Shareholders have been substantially diluted in the past year (50% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Share price has been volatile over the past 3 months (7.3% average weekly change).
お知らせ • Aug 12CanBas Co., Ltd., Annual General Meeting, Sep 26, 2023CanBas Co., Ltd., Annual General Meeting, Sep 26, 2023.
New Risk • Aug 07New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 50% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 15% per year over the past 5 years. Shareholders have been substantially diluted in the past year (50% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Share price has been volatile over the past 3 months (6.8% average weekly change).
お知らせ • Jun 03+ 1 more updateCanBas Co., Ltd. to Report Fiscal Year 2023 Results on Aug 10, 2023CanBas Co., Ltd. announced that they will report fiscal year 2023 results on Aug 10, 2023
お知らせ • May 20CanBas Co., Ltd. announced that it expects to receive ¥729 million in fundingCanBas Co., Ltd. announced a private placement of 500,000 common shares at an issue price of ¥1,458 per share for the gross proceeds of ¥729,000,000 on May 18, 2023. The transaction will include participation from new investors Long Corridor Alpha Opportunities Master Fund and MAP246 Segregated Portfolio. The company will issue shares through third-party allotment. The transaction has been approved by the board of directors of the company. The transaction is expected to close on June 2, 2023.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 3 highly experienced directors. 2 independent directors (5 non-independent directors). Independent External Director Toshio Furuta was the last independent director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Sep 01+ 2 more updatesCanBas Co., Ltd. to Report Q3, 2023 Results on May 12, 2023CanBas Co., Ltd. announced that they will report Q3, 2023 results on May 12, 2023
Reported Earnings • Aug 15Full year 2022 earnings released: JP¥88.26 loss per share (vs JP¥70.01 loss in FY 2021)Full year 2022 results: JP¥88.26 loss per share (down from JP¥70.01 loss in FY 2021). Net loss: JP¥855.0m (loss widened 61% from FY 2021). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
お知らせ • Aug 14CanBas Co., Ltd., Annual General Meeting, Sep 27, 2022CanBas Co., Ltd., Annual General Meeting, Sep 27, 2022.
お知らせ • Jun 03CanBas Co., Ltd. to Report Fiscal Year 2022 Results on Aug 12, 2022CanBas Co., Ltd. announced that they will report fiscal year 2022 results on Aug 12, 2022
Reported Earnings • May 19Third quarter 2022 earnings released: JP¥22.78 loss per share (vs JP¥9.24 loss in 3Q 2021)Third quarter 2022 results: JP¥22.78 loss per share (down from JP¥9.24 loss in 3Q 2021). Net loss: JP¥224.0m (loss widened 215% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 3 highly experienced directors. 2 independent directors (5 non-independent directors). Independent External Director Toshio Furuta was the last independent director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Feb 12First half 2022 earnings: Revenues and EPS in line with analyst expectationsFirst half 2022 results: JP¥39.87 loss per share (up from JP¥43.73 loss in 1H 2021). Net loss: JP¥359.0m (loss widened 16% from 1H 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.
Reported Earnings • Nov 12First quarter 2022 earnings released: JP¥22.38 loss per share (vs JP¥29.76 loss in 1Q 2021)First quarter 2022 results: Net loss: JP¥198.0m (loss narrowed 5.7% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings.
お知らせ • Sep 03CanBas Co., Ltd. announced that it expects to receive ¥16.38843 million in fundingCanBas Co., Ltd. announced a private placement of 55,554 units at a price of ¥295 for gross proceeds of ¥16,388,430 on September 2, 2021. The company has issued through 17th Stock Acquisition Rights. As part of the transaction, no monetary payment is required in exchange for the bonds with Stock Acquisition Rights.
Reported Earnings • May 17Third quarter 2021 earnings released: JP¥9.24 loss per share (vs JP¥19.46 loss in 3Q 2020)The company reported a decent third quarter result with reduced losses and improved control over expenses, although revenues were flat. Third quarter 2021 results: Revenue: JP¥27.0m (flat on 3Q 2020). Net loss: JP¥71.0m (loss narrowed 47% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.
Reported Earnings • Feb 14Second quarter 2021 earnings released: JP¥14.04 loss per share (vs JP¥18.59 loss in 2Q 2020)The company reported a decent second quarter result with reduced losses and improved control over expenses, although revenues were flat. Second quarter 2021 results: Revenue: JP¥28.0m (flat on 2Q 2020). Net loss: JP¥100.0m (loss narrowed 21% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Jan 05New 90-day low: JP¥426The company is down 40% from its price of JP¥710 on 07 October 2020. The Japanese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 11% over the same period.
Is New 90 Day High Low • Dec 16New 90-day low: JP¥457The company is down 35% from its price of JP¥703 on 17 September 2020. The Japanese market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period.
お知らせ • Nov 06CanBas Co., Ltd. announced that it expects to receive ¥9.678321 million in funding from Advantage Partners, Inc. and other investorsCanBas Co., Ltd. (TSE:4575) announced that it will issue 17,629 16th Stock Acquisition Rights at a price of ¥549 per stock acquisition right for the gross proceeds of ¥9,678,321 on November 5, 2020. The stock acquisition rights are converted into 1,762,900 common shares and have initial exercise of ¥610 per share and minimum exercise price of ¥305 per share. The expected fund raise through exercise of stock acquisition right are ¥1,085,047,321. The transaction include participation from existing investor Inflexion II Fund L.P., funds managed by Advantage Partners, Inc. for 4,524 stock acquisition rights, Investment Limited Partnership InfleXion II for 11,612 stock acquisition rights and Flagship Asset Management Investment Association No. 90 for 1,493 stock acquisition rights.
お知らせ • Sep 12CanBas Co., Ltd. to Report Q1, 2021 Results on Nov 13, 2020CanBas Co., Ltd. announced that they will report Q1, 2021 results on Nov 13, 2020